HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty.

Abstract
A long-acting analog of LRH (LRHa) has been shown to suppress pituitary gonadotropin and estradiol secretion to prepubertal levels in girls with idiopathic true precocious puberty. We treated six boys, aged 1-6 yr, with true precocious puberty due to hypothalamic hamartoma for 6-24 months with daily sc injections of LRHa. The patients had enlarged testes (6-25 ml), Tanner stage II-IV pubic hair, facial and axillary hair, increased growth rate, and an advanced bone age. Frequent erections occurred in all patients. Computed tomography of the head showed abnormalities characteristic of hypothalamic hamartoma (0.5-3 cm in diameter) in each boy. Each patient had measurable LH and FSH levels, with pulsed nocturnal secretion, and pubertal LH and FSH responses to LRH. Serum testosterone was in the range for normal adult men (200-600 ng/dl). LRHa significantly decreased basal LH (P less than 0.005) and FSH levels (P less than 0.01), LRH-stimulated gonadotropin levels (P less than 0.005), and serum testosterone levels (P less than 0.005). Testis size decreased significantly (P less than 0.005). Annualized growth velocity (centimeters per yr) decreased significantly compared to the pretreatment growth rate (P less than 0.01). Bone age advancement per yr slowed significantly during the course of LRHa treatment (P less than 0.01). Pubic hair, facial hair, and erections decreased in all patients. LRHa is an effective treatment for boys with precocious puberty associated with hypothalamic hamartoma. Chronic therapy will be required, however, to assess the ultimate effect of LRHa.
AuthorsF Comite, O H Pescovitz, K G Rieth, A J Dwyer, K Hench, A McNemar, D L Loriaux, G B Cutler Jr
JournalThe Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 59 Issue 5 Pg. 888-92 (Nov 1984) ISSN: 0021-972X [Print] United States
PMID6434587 (Publication Type: Journal Article)
Chemical References
  • Triptorelin Pamoate
  • Gonadotropin-Releasing Hormone
  • Testosterone
  • Tryptal
  • Luteinizing Hormone
  • Follicle Stimulating Hormone
Topics
  • Bone Development (drug effects)
  • Child, Preschool
  • Follicle Stimulating Hormone (blood)
  • Gonadotropin-Releasing Hormone (analogs & derivatives, therapeutic use)
  • Growth (drug effects)
  • Hamartoma (blood, complications, drug therapy)
  • Humans
  • Hypothalamic Neoplasms (blood, complications, drug therapy)
  • Infant
  • Luteinizing Hormone (blood)
  • Male
  • Puberty, Precocious (blood, drug therapy, etiology)
  • Testosterone (blood)
  • Triptorelin Pamoate (analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: